Macular Degeneration Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Macular Degeneration stocks.

Macular Degeneration Stocks Recent News

Date Stock Title
Jul 31 RGNX Regenxbio Q2 2024 Earnings Preview
Jul 31 REGN Regeneron Pharmaceuticals Q2 2024 Earnings Preview
Jul 31 REGN Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
Jul 30 RGNX Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX)
Jul 30 REGN Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Jul 30 REGN Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
Jul 30 REGN Roche’s Vabysmo challenges Eylea dominance with third European indication
Jul 30 OTLK Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
Jul 30 REGN BioNTech posts mid-stage win for mRNA cancer drug with Regeneron’s Libtayo
Jul 30 GILD Compugen receives FDA approval for Phase I trial of solid tumour treatment
Jul 30 REGN The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Regeneron and Optex Systems
Jul 29 GILD Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
Jul 29 REGN Top Analyst Reports for Goldman Sachs, RTX & Regeneron
Jul 29 REGN Countdown to Regeneron (REGN) Q2 Earnings: Wall Street Forecasts for Key Metrics
Jul 29 GILD Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
Jul 29 GILD How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Jul 29 REGN Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Jul 28 GILD Gilead Sciences, Inc.'s (NASDAQ:GILD) one-year returns climbed after last week's 6.1% gain, institutional investors must be happy
Jul 27 REGN Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Jul 27 GILD A Look At Gilead Sciences After Its Recent Weakness
Macular Degeneration

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.Macular degeneration typically occurs in older people. Genetic factors and smoking also play a role. It is due to damage to the macula of the retina. Diagnosis is by a complete eye exam. The severity is divided into early, intermediate, and late types. The late type is additionally divided into "dry" and "wet" forms with the dry form making up 90% of cases.Preventive efforts include exercising, eating well, and not smoking. Antioxidant vitamins and minerals do not appear to be useful for prevention. There is no cure or treatment that returns vision already lost. In the wet form, anti-VEGF medication injected into the eye or less commonly laser coagulation or photodynamic therapy may slow worsening. Supplements in those who already have the disease may slow progression.In 2015 it affected 6.2 million people globally. In 2013 it was the fourth most common cause of blindness after cataracts, preterm birth, and glaucoma. It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group. About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.

Browse All Tags